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CHM-1 (2-fluoro-6,7-methylenedioxy-2-phenyl-4-quino-
lone) has been identified as a potent antitumor agent in human
hepatocellular carcinoma; however, its role in tumor angiogen-
esis is unclear. This study investigated the effects of CHM-1 and
themechanisms by which it exerts its antiangiogenic and vascu-
lar disrupting properties. Using a xenograft model antitumor
assay, we found that CHM-1 significantly inhibits tumor growth
and microvessel formation. Flow cytometry, immunofluores-
cence microscopy, and cell death enzyme-linked immunosor-
bent assay kit revealed that CHM-1 inhibits growth of human
umbilical vein endothelial cells (HUVEC) by induction of apo-
ptotic cell death in a concentration-dependentmanner. CHM-1
also suppresses HUVEC migration and capillary-like tube for-
mation.Wewere able to correlate CHM-1-induced apoptosis in
HUVEC with the cleavage of procaspase-3, -7, and -8, as well as
with the cleavage of poly(ADP-ribose) polymerase by Western
blotting assay. Such sensitization was achieved through up-reg-
ulation of death receptor 5 (DR5) but not DR4 or Fas. CHM-1
was also capable of increasing the expression level of p53, and
most importantly, the induction of DR5 by CHM-1 was abol-
ished by p53 small interfering RNA. Taken together, the results
of this study indicate that CHM-1 exhibits vascular targeting
activity associated with the induction of DR5-mediated endo-
thelial cell apoptosis through p53 up-regulation, which suggests
its potential as an antivascular and antitumor therapeutic agent.
In neoplasm, malignant angiogenesis and tumor mortality
are highly associated with each other. Almost every step of
aggressive tumor growth and metastatic dissemination relies
on a functional vascular network to provide tumor cells with
oxygen and nutrients and to remove waste products associated
with tumor metabolism, a crucial hallmark of cancer (1). Now-
adays, several antiangiogenic strategies have been developed to
inhibit tumor growth andmetastasis. In addition to the indirect
interference of proangiogenic communication between the
tumor and endothelial cell compartments, several recent
reports have suggested that the induction of apoptosis in pro-
liferation of endothelial cells may represent a potential thera-
peutic strategy in the treatment of neovascularization-related
diseases (2–4). For instance, numerous natural angiogenic
inhibitors, such as endostatin, angiostatin, and throm-
bospondin-1, act in part through selective triggering apoptosis
in endothelial cells, resulting in vascular regression (5, 6). Sev-
eral antitubulin-binding agents (e.g.CA-4-phosphate, ZD6126,
and TZT-1027) and flavonoids (5,6-dimethylxanthenone-4-
acetic acid) have demonstrated the ability to induce apoptosis
of tumor vascular endothelial cells, leading to the rapid collapse
and obstruction of tumor vessels and ultimately causing a
tumor vascular shutdown effect (7).
Apoptosis is an intracellular suicide program possessing
morphologic characteristics and biochemical features,
including chromatin condensation, nuclear DNA fragmen-
tation, cell shrinkage, membrane blebbing, and the forma-
tion of apoptotic bodies (8, 9). To date, two major apoptotic
pathways have been described as follows: the extrinsic death
receptor-mediated pathway and the intrinsic mitochondri-
on-initiated pathway. An apoptotic event engages the intrin-
sic mitochondrion-dependent processes, affecting mito-
chondrial permeability and resulting in cytochrome c release
and activation of caspase-9. The extrinsic apoptotic pathway
originates at membrane death receptors (DRs)4 such as Fas
(CD95/APO-1), DR4 (TRAIL-R1), and DR5 (TRAIL-R2) and
then engages the intracellular apoptotic machinery involv-
ing adaptor molecules and proximal caspase-8 as well as dis-
tal executioner caspases (10, 11).
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p53-inducible proapoptotic genes trigger apoptosis through
both DR andmitochondrial apoptotic pathways (12). DRs such
as DR4, DR5, and Fas are increased by p53-dependent tran-
scriptional activation (13). Interaction of tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL), a member of the
tumor necrosis factor family of proteins, with DR4 and DR5
leads to recruitment of the adaptor protein FADD and initiator
caspase-8 to the death-inducing signaling complex (14). This
results in enzymatic activation of caspase-8, which in turn acti-
vates a downstream caspase cascade in the presence or absence
of mitochondrial amplification machinery (15, 16).
The 2-phenyl-4-quinolones and related compounds, a series
of synthetic quinolone derivatives, were found to inhibit tubu-
lin polymerization and disrupt microtubule organization, and
they act as antimitotic agents (17–21). It was reported that the
2-phenylpyrroloquinolin-4-ones have antitumor activity in
vitro and in vivo (22). In our previous study, we had speculated
that CHM-1, which was identified from a synthetic 6,7-substi-
tuted 2-phenyl-4-quinolone derivative, potently inhibits
hepatocyte growth factor-induced cell invasion in the human
hepatocellular carcinoma cell line, SK-Hep-1, and exhibits a
novel antimitotic antitumor activity against human hepatocel-
lular carcinoma both in vitro and in vivo (23, 24). Recently, it
was reported that CHM-1 has anticancer activity in human
osteogenic sarcoma U-2 OS cells (25). However, there have
been no reports on the possible vascular targeting effect of
CHM-1. In this study, we investigated the mechanism of apo-
ptosis induction by CHM-1 in endothelial cells. Our results
suggest that CHM-1 targets tumor microvasculature through
p53-mediated DR5 up-regulation.
EXPERIMENTAL PROCEDURES
Reagents—CHM-1was synthesized by Prof. S.-C. Kuo (Grad-
uate Institute of Pharmaceutical Chemistry, School of Medi-
cine, China Medical University). Propidium iodide and 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT)were obtained fromSigma. 4,6-Diamidino-2-phenylin-
dole was purchased from Roche Diagnostics. Antibody to
caspase-3 was purchased from Imgenex (San Diego). Antibod-
ies against PARP and caspase-9 were purchased from Cell Sig-
naling Technology (Beverly, MA). Antibodies to caspase-6,
caspase-7, caspase-8, and p53 were purchased from BD Bio-
sciences. Antibodies against DR4 and DR5 were purchased
from Novus Biologicals Inc. (Littleton, CO). Z-VAD-fmk was
from R & D Systems (Minneapolis, MN). p53 small interfering
RNA (siRNA) was obtained from Invitrogen. DR5 siRNA was
purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Cell Culture and RNA Interference Transfection—Human
umbilical vein endothelial cells (HUVEC) were freshly isolated
from human umbilical cords and cultured as described previ-
ously (26). The human colorectal cancer HT-29 cell line was
grown in RPMI 1640 medium with 10% heat-inactivated fetal
bovine serum and penicillin (100 units/ml)/streptomycin (100
g/ml) (27). These cells were maintained at 37 °C in a humidi-
fied incubator with 5% CO2 atmosphere. For the transfection
procedure, cells were grown to 70% confluence in a culture
dish, and p53 siRNA orDR5 siRNAwas transfected using Lipo-
fectamine 2000 (Invitrogen). Following transfection, cells were
seeded and treated with CHM-1 and then analyzed usingMTT
assay, Western blot analysis, or RT-PCR.
In Vivo Matrigel Plug Assay—MatrigelTM basement mem-
brane matrix (BD Biosciences) mixed with heparin (10 units/
ml) and endothelial growthmedium-2 (EGM2),with orwithout
CHM-1, were injected subcutaneously in the midventral
abdominal region of C57BL/6 mice and permitted to solidify.
On day 7,Matrigel pellets were harvested, fixed with 4% forma-
lin, embedded in paraffin, and subsequently processed forMas-
son’s Trichrome staining. Hb was estimated by the Drabkin’s
method with Drabkin’s reagent kit (Sigma) to quantify blood
vessel formation.
HT-29 Xenograft Models—CHM-1-phosphate was dissolved
completely in a vehicle mixture of DMSO/cremophor EL/sa-
line. Male SCID (severe combined immunodeficiency) mice
were implanted subcutaneously with 1  107 HT-29 human
colon cancer cells per mouse. Mice bearing established tumors
(100 mm3) were randomized into two groups, and the agent
treatment was initiated. CHM-1-phosphate at a dose of 25
mg/kg was administered intravenously every day. Tumors were
measured every 3–4 days with a caliper, and tumor volumes
were calculated using the following formula: volume (V) 
lw2/2, with l being the length and the w being the width. Histo-
logical analysis was done on formalin-fixed, paraffin-embedded
xenograft tissue samples. The primary antibody CD31 (Abcam,
Cambridge, MA) was used in this study to permit determina-
tion of the blood vessels. The protocols of all animal experi-
ments were accordance with institutional guidelines for animal
welfare.
Cell Viability and Growth—Cell viability was determined by
measuring the ability of cells to transform the yellow tetrazo-
lium salt MTT into formazan crystal, a purple dye. Cells (5 
103 cells per well) were seeded in 96-well culture plates over-
night for attachment and then were incubated with or without
CHM-1 at different concentrations for 24 and 48 h. After the
incubation, 0.5 mg/ml MTT solution was added to each well,
and the plates were incubated at 37 °C for an additional 4 h. The
color intensity of the formazan solution, which reflects the cell
growth condition, was measured at 550 nm using an ELISA
reader.
Endothelial Cell Migration Assay—HUVEC were plated (in
complete medium) in the upper layer of an 8-m pore size
transwell. Cells were allowed to adhere for 4 h at 37 °C and then
replaced the 2% heat-inactivated fetal bovine serum/M199
medium, with or without CHM-1, for 8 h at 37 °C in a humidi-
fied atmosphere of 95% air, 5% CO2. At the same time, 5%
heat-inactivated fetal bovine serum/M199 medium was added
in the lower chambers. At the end of treatment, condition
medium was removed from both upper and lower layers of
chambers, and the membranes were fixed and stained with
crystal violet for 10min and then rinsed in water. Cells remain-
ing on the filter side of the upper chamber were cleaned by
gently wiping with a cotton swab. As the membranes dried, the
cells that had migrated to the underside of the filters were pho-
tographed with microscope. To quantify the cells that had
migrated through the membrane pores, the filters were gently
cut from the chamber, and the dye was eluted in a solution
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containing sodium citrate and then
determined using an ELISA reader
at A550.
In Vitro Tube Formation Assay on
Matrigel—3  104 HUVEC were
incubated in the absence or pres-
ence of CHM-1 and then seeded in a
96-well culture plate precoated with
Matrigel (BD Biosciences). The
tubular formationwas observed and
photographed under a phase con-
trast microscope after incubation at
37 °C in a humidified chamber with
5% CO2 for 6 h. The quantitative




phological analysis of cells apoptosis
was examined by a phase contrast
microscopy (Nikon). CHM-1-in-
duced apoptotic death of HUVEC
was identified by 4,6-diamidino-2-
phenylindole staining. Cells were
seeded into 8-well slide chambers
the day before treatment. After the
cells were incubatedwith CHM-1 (3
M) for 24 h, they were washed
twice with ice-cold phosphate-buff-
ered saline (PBS) and fixed in 4%
methanol at 20 °C for 10 min. The
cells were then incubated in 4,6-
diamidino-2-phenylindole for 5min
at room temperature. The slides
were washed three times with PBS,
and nuclear morphological alterna-
tions were then analyzed using a
Zeiss fluorescence microscope. For
quantitative assessment of oligonu-
cleosomal DNA fragmentation, Cell
Death ELISAPLUS kit (Roche Diag-
nostics) was used to determined
apoptosis. Spectrophotometric data
at a wavelength of 405 nm, with a
reference of 490 nm, was acquired
on a microplate reader.
Flow Cytometric Analysis—The
cells (80% confluence) were 2% fetal
bovine serum/M199 medium-
starved for 24 h to synchronize
them in the G0 phase of the cell
cycle, and then they treated with
CHM-1 for the indicated time. The
cells were trypsinized after treat-
ment, washed with cold PBS, and
centrifuged. The pellet was fixed in
75% ethanol overnight at 20 °C.
After centrifugation, the fixed cells
FIGURE 1. Inhibitory effect of CHM-1 on in vivo angiogenesis. A, Matrigel-plug bioassay for antiangiogenesis
effect of CHM-1 in C57BL/6 mice. Top panel, representative macroscopic pictures of the Matrigel plugs after
excision. Middle panel, histological sections of the Matrigel plugs stained with Masson’s trichrome. Bottom
panel, quantization of functional vasculature inside the Matrigel plugs by measuring Hb content using Drab-
kin’s reagent. Data represent the mean  S.E. from four independent experiments. ***, p  0.001 as compared
with the control (CTL) group. B, efficacy of CHM-1 on the growth of HT-29 human colon tumor xenografts and
vascularization in SCID mice. Treatment with CHM-1 abrogated the tumor. Left panel, tumor growth is pre-
sented as the mean tumor volume (mm3)  S.E. Tumor volume was determined by caliper measurements and
was calculated as the product of 1⁄2  length  width2. Right panel, body weight (g) of the mice. Each value
represents the mean of at least seven animals. *, p  0.05 as compared with the control (CTL) group. C, blood
vessels of formalin-fixed paraffin-embedded sections from a xenograft tumor were detected by anti-CD31
immunofluorescence staining. Brown color, CD31-positive blood vessels. The images of vessel area in tumor
sections stained with an antibody to CD31 were analyzed using an Image-Pro Plus software.
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were washed once with PBS and incubated in 0.1 mol/liter
phosphate/citric acid buffer (0.2 mol/liter Na2HPO4, 0.1 mol/
liter citric acid, pH 7.8) for 30 min at room temperature in
darkness. The cells were then centrifuged and resuspended
with 0.5 ml of propidium iodide
working solution (100 g/ml
RNase, 80 g/ml propidium iodide,
0.1% Triton X-100 in PBS). The
stained cells were sorted by FACS-
can flow cytometry and analyzed
using CellQuest software (BD
Biosciences).
Preparation of Cytosolic and
Nuclear Extracts—For nuclear ex-
tracts, treated cells were washed
with ice-cold PBS, scraped into
buffer A (10 mM Hepes, pH 7.9, 1.5
mM MgCl2, 10 mM KCl, 0.5 mM di-
thiothreitol, 1% Nonidet P-40, and
protease inhibitors), and incubated
on ice for 15 min. Nuclei were sepa-
rated from the cytosol by centrifu-
gation at 2,500 rpm for 5min at 4 °C.
The supernatants (cytosolic frac-
tion) were removed, and the pellets
were suspended in buffer C (20 mM
Hepes, pH7.9, 25%glycerol, 420mM
NaCl, 1.5mMMgCl2, 0.2mMEDTA,
0.5 mM dithiothreitol, and 0.2 mM
phenylmethylsulfonyl fluoride), in-
cubated on ice for 30 min, and then
centrifuged at 13,000 rpm for 10
min at 4 °C, and the supernatants
were frozen at 20 °C.
Western Blot Analysis—The cells
were harvested and lysed in an ice-
cold modified RIPA buffer (150 mM
NaCl, 1 mM EDTA, 1% Nonidet
P-40, 0.5% sodium deoxycholate,
0.1% SDS, 20 mM Tris, pH 8.0) that
was supplemented with protease
inhibitors (1 g/ml aprotinin, 1
g/ml leupeptin, 0.5 M NaF, 0.5 M
Na3VO4, 1 mM phenylmethylsulfo-
nyl fluoride) for 1 h on ice. Cellular
lysates were centrifuged at 13,000
rpm for 30 min at 4 °C to remove
insolublematerial. The protein con-
centration was determined by the
Bio-Rad protein assay according to
the manufacturer’s instructions.
Equal amounts of protein were sep-
arated on SDS-polyacrylamide gel
electrophoresis gels, and the protein
was subsequently transferred to
nitrocellulose membranes by elec-
troblotting 2.5 h at 400 mA. The
membranes were blocked with 5%
nonfat milk in PBS for 1 h and washed three times with PBS,
0.1% Tween 20. After that, the membranes were probed for
desired proteins using specific primary antibodies overnight at
4 °C. Membranes were then washed four times with PBS, 0.1%
FIGURE 2. Inhibitory effect of CHM-1 on in vitro angiogenesis. A, cell viability (for 24 and 48 h) was deter-
mined using MTT reduction assay. B, inhibition of HUVEC migratory activity by CHM-1 was measured by a
transwell migration assay. Upper panel, microscopic appearance of the migratory cells on the underside of the
8-m pore size transwell membrane. Lower panel, quantitative data regarding endothelial cell migration. Data
represent the mean  S.E. from four independent experiments. , p  0.001 as compared with the basal
group; *, p  0.05; **, p  0.01 as compared with the control (CTL) group. C, in vitro Matrigel-based tubule
formation assay. Upper panel, inhibitory effect of CHM-1 on the formation of endothelial cells capillary-like
tubular structures as observed with a microscope. Magnification is 100. Lower panel, quantification of the
average tubular length was determined by image analysis software. Data represent the mean  S.E. from four
independent experiments. ***, p  0.001 as compared with the control (CTL) group.
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Tween 20 followed by peroxidase-conjugated appropriate sec-
ondary antibody and visualized by ECL detection system.
RT-PCR—Total cellular RNA was extracted from HUVEC
with TRIzol reagent (Invitrogen). First strand cDNA synthesis
was performed with 5 g of RNA and 500 ng/l random prim-
ers at 65 °C for 5min and then usingMoloneymurine leukemia
virus-RT at 37 °C for 1 h. The single-stranded cDNAwas ampli-
fied by PCR. The amplification mixture (final volume, 20 l)
contained 10 Taq DNA polymer-
ase buffer, 10 mM dNTPs, 10 M
primer pair, 0.5 l of Taq DNA po-
lymerase, cDNA, and diethyl pyro-
carbonate water. The primers and
PCR conditions used for DR5 were
according to Cao et al. (28). PCR
products were separated by 1.5%
agarose gel electrophoresis and
detected by ethidium bromide
staining.
Statistical Analysis—Data are
expressed as themean S.E. for the
indicated number of separate exper-
iments. Means were checked for
statistical difference using the t test,
andp values less than 0.05were con-
sidered significant. (*, p  0.05; **,
p  0.01; and ***, p  0.001). The
significance of differences of in vivo
xenograft data were analyzed by the
Mann-Whitney U test.
RESULTS
CHM-1 Inhibits Angiogenesis in
Vivo—TodeterminewhetherCHM-
1 has antiangiogenic activities, an in
vivo mouse Matrigel plug assay was
first carried out. Angiogenesis was
induced in EGM2-treated Matrigel
plugs (control). However, CHM-1
potently inhibited EGM2-induced
blood vessel growth in a concentra-
tion-dependent manner (Fig. 1A,
top panel). We performed a histo-
logical examination to confirm the
formation of numerous blood ves-
sels. The stained section of the
Matrigel plugs in the control groups
showed abundant erythrocyte-filled
vessels, indicating the formation of
a functional vasculature in the
Matrigel, whereas it was not
observed in the CHM-1-treated
plugs (Fig. 1A, middle panel). We
also measured the hemoglobin con-
tent to quantify the antiangiogenic
effect induced by the treatmentwith
CHM-1. The hemoglobin quantity
was markedly reduced by treatment
with CHM-1 as compared with the control groups (Fig. 1A,
bottom panel). To test the hypothesis that CHM-1 may disrupt
vasculaturewithin tumors, anHT-29 tumor xenograftmodel in
SCID mice was used. CHM-1 treatment significantly inhibited
tumor growth, without a toxic effect on body weight (Fig. 1B,
left and right panel).We also performed immunohistochemical
analysis of tissue samples with CD31 antibody, which is a spe-
cific endothelial marker for estimating whether CHM-1 sup-
FIGURE 3. CHM-1 triggers growth inhibition and apoptosis in HUVEC. A, cells were treated with 3 M CHM-1
for the indicated times. The appearance of a sub-G1 population was analyzed by FACScan flow cytometric
analysis. Data represent the mean  S.E. from four independent experiments. ***, p  0.001 as compared with
the control group. B, upper panel displays the characteristic morphological features of apoptosis in cells after
24 h of treatment. In a parallel experiment, the cells were stained with 4,6-diamidino-2-phenylindole (DAPI)
solution. Stained nuclei were then observed under a fluorescent microscope. C, quantitative analysis of apo-
ptotic cell death after 24 h of CHM-1 treatment. The amount of DNA fragmentation, a hallmark of apoptosis,
was evaluated with a cell death ELISAPLUS kit.
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presses vasculature within tumors. In the treated group, vessels
were sparsely distributed throughout the tumor, as evidenced
by the lack of CD31 staining (Fig. 1C). Taken together, these
results demonstrated antitumor activity of CHM-1 in vivo
through the disruption of tumor microvasculature.
CHM-1 Inhibits Angiogenesis in Vitro—To assess the vascu-
lar targeting potential of CHM-1, we carried out an angiogenic
cellular functional assay using HUVEC. We first executed an
MTT assay to measure the effect of CHM-1 on the growth of
HUVEC. The addition of CHM-1 resulted in time- and
concentration-dependent cell growth inhibition, with IC50 val-
ues of 3.9 M (24 h) and 1.1 M (48 h), respectively (Fig. 2A). To
examine whether CHM-1 affected the migratory behavior of
endothelial cells, we performed a transwell migration assay. As
illustrated in Fig. 2B, CHM-1 inhibited cell migration in a
concentration-dependent manner.We proceeded to conduct a
tube formation assay to estimate the effect of CHM-1 on mor-
phological differentiation of the HUVEC. HUVEC were placed
on a Matrigel-coated plate where they formed many strong,
robust elongated tube-like structures in the presence of EGM2
(control). In contrast, treatment with CHM-1 strongly inhib-
ited the formation of tube-like networks in a con-
centration-dependent manner.
Capillary tubes were counted in five
randomly selected areas of samples
undermicroscopic field and showed
a 32.4% (p  0.001), 67.1% (p 
0.001), and 98% (p  0.001)
decrease following 0.1, 0.3, and 1M
CHM-1 treatment, respectively
(Fig. 2C). Overall, these results pro-
vided strong evidence of the antian-
giogenic activity of CHM-1 in vitro.
CHM-1 Inhibits Cell Growth and
Induces Apoptosis in HUVEC—To
determine the mechanism of the
antiangiogenic activity of CHM-1,
we analyzed the effect of CHM-1 on
cell cycle distribution using flow
cytometry to investigate whether
CHM-1-induced growth inhibition
in HUVECwas accompanied by cell
cycle arrest. Treatment with
CHM-1 induced an accumulation of
cells in the G2/M phase, accompa-
nied by a time-dependent increase
in the proportion of apoptotic cells,
as reflected by the presence of a
peak in the number of sub-G1 cells
(Fig. 3A). We next examined
whether CHM-1-induced cell death
showed the cytological features that
are typically seen in cells undergo-
ing apoptosis. As shown in Fig. 3B,
CHM-1 induced morphological
changes and chromatin condensa-
tion, whereas untreated control
cells displayed intact morphology
and nuclear structure. Quantitative assessment of oligonucleo-
somal DNA fragmentation showed that CHM-1-treated cells
increased this feature in a concentration-dependent manner
(Fig. 3C). Overall, these results suggested that CHM-1 causes
apoptosis in HUVEC.
CHM-1 Triggers the Extrinsic Apoptosis Pathway—The
induction of CHM-1-induced apoptosis was additionally con-
firmed by the cleavage of PARP, which serves as a reliable bio-
chemical marker of cells undergoing apoptosis. A decrease in
total PARPwith a concomitant increase in PARP cleavage frag-
ments was observed in CHM-1-treated cells in a time- and
concentration-dependent manner (Fig. 4,A and B). We further
documented the involvement of various caspases duringCHM-
1-triggered cell death. Treatment with CHM-1 resulted in the
induction of cleaved forms of caspase-3, -7, and -8, but not -9
(Fig. 4,A and B), indicating activation of the extrinsic apoptotic
pathway. Pretreatment with the pan-caspase inhibitor Z-VAD-
fmk was shown to reverse CHM-1-induced caspase-3 and
PARP cleavage (Fig. 4C).
CHM-1 Induces Apoptosis via Up-regulation of DR5—Be-
cause CHM-1 induced the cleavage of initiator caspase-8, we
speculated that its proapoptotic response could bemediated via
FIGURE 4. CHM-1 induces proteolytic cleavage of caspases and PARP in HUVEC. Cells were incubated in the
absence or presence of CHM-1 for the indicated time (A) or concentration (B) and then harvested and prepared
for detection of caspase-3, -7, -8, and -9 and PARP cleavage using Western blotting. C, pretreatment with
Z-VAD-fmk for 1 h and then incubation with CHM-1 for another 24 h. Cells lysates were collected for Western
blotting to detect the cleavage of caspase-3 and PARP. The arrowheads indicate cleavage forms. GAPDH,
glyceraldehyde-3-phosphate dehydrogenase; CTL, control.
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the death receptor-signaling pathway. As shown in Fig. 5A,
CHM-1 treatment was found to cause a time-dependent up-
regulation of the DR5 protein without significant change in
the expressions of FasL, TRAIL, Fas, and DR4. To confirm
the effect of CHM-1 on DR5, we further measured the DR5
expression level at the cell surface using flow cytometry.
CHM-1 consistently elevated the cell surface expression of
DR5 but not DR4 in HUVEC (Fig. 5B). On the other hand, we
also found that CHM-1 induced mRNA expression of DR5,
reaching a maximum level at 1 h (Fig. 5C). To further evalu-
ate the role of DR5 in CHM-1-induced apoptotic signaling in
HUVEC, we used DR5 siRNA to block CHM-1-induced DR5
up-regulation and then determined its effect on CHM-1-in-
duced apoptosis. The prevention of
PARP and caspase-3 cleavage due to
CHM-1 treatment was correlated
with the decrease in DR5 protein
levels by the transfection of DR5
siRNA (Fig. 5D, upper panel). Using
the crystal violet assay, we also
found that CHM-1-induced growth
inhibition in HUVEC was nearly
suppressed by DR5 siRNA (Fig. 5D,
lower panel). Taken together, these
results suggested that DR5 up-regu-
lation plays an important role in
CHM-1-induced apoptosis in
HUVEC.
Up-regulation of DR5 by CHM-1
Correlates with the Increased Ex-
pression of p53—In a previous study,
we found a great deal of evidence
indicating that p53, a transcrip-
tional factor, could activate the
extrinsic DR pathway through the
induction of genes encoding trans-
membrane proteins such as DR5
(12). Therefore, we first determined
whether CHM-1 up-regulated the
expression of p53, thereby regulat-
ing the expression of DR5 in
HUVEC. As shown in Fig. 6A, treat-
ment with CHM-1 increased the
p53 protein level and translocated
p53 into the nucleus, which is coin-
cident with the change in DR5 pro-
tein level. Next, to elucidate
whether p53 plays a critical role in
CHM-1-induced DR5 up-regula-
tion and apoptosis, we manipulated
p53 expression using p53 siRNA.
The data showed that knockdownof
p53 attenuated the induction of
DR5 as well as the cleavage of PARP
and caspase-3 (Fig. 6B) and conse-
quently prevented growth inhibi-
tion and apoptosis in cells treated
with CHM-1 (Fig. 6C).
DISCUSSION
In our previous study, CHM-1 was shown to possess potent
cytotoxic activity in vitro and in vivo. CHM-1was found to bind
to tubulin at the colchicine site, causing G2/M phase cell arrest
and inducing cancer cell apoptosis (24). Recently, several stud-
ies have consistently reported that somemicrotubule-targeting
agents, particularly those agents that work by acting at the col-
chicine-binding site of the -subunit of endothelial tubulin,
may disrupt the endothelial cytoskeleton, leading to loss of
blood flow and tumor-related endothelial cell apoptosis and
eventually tumor vasculature disruption (29, 30). In this study,
we first demonstrated that CHM-1 suppressed tumor growth
FIGURE 5. CHM-1-induced apoptosis by up-regulation of DR5. A, cells were exposed to CHM-1 (3 M) for
the indicated times and then harvested. Cell extracts were then prepared, followed by immunoblotting
using antibodies against DRs (anti-Fas, anti-DR4, and anti-DR5) and ligands (anti-FasL and anti-TRAIL).
B, HUVEC were incubated with CHM-1 (3 M) for 24 h, and the levels of DR4/DR5 expression were analyzed
by flow cytometry. C, HUVEC were treated with CHM-1 (3 M) for the indicated times, and the expression
of DR5 mRNA was then measured by RT-PCR analysis. D, knockdown of DR5 by DR5 siRNA attenuates
CHM-1-induced apoptosis. HUVEC were transfected with or without DR5 siRNA and then incubated with
or without CHM-1 (3 M) for an additional 24 h. Upper panel, total cellular lysates were subjected to
Western blot analysis of DR5, PARP, and caspase-3. Lower panel, cell viability was analyzed by crystal violet
assay and is represented as the percentage (%) survival by setting untreated cells as 100%. GAPDH,
glyceraldehyde-3-phosphate dehydrogenase.
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through induction of endothelial cell apoptosis, which dis-
rupted tumor microvascular networks.
We provided strong evidence that CHM-1 significantly
inhibits tumor angiogenesis using Matrigel-plug and xenograft
animalmodels.We then showed thatCHM-1blocked endothe-
lial cell functions such as cell survival, migration, and tube for-
mation, in agreement with our in vivo findings. The previous
study demonstrates that CHM-1 significantly inhibits the
migration of U-2 OS cell migration at 3 M (25); however, the
inhibition of endothelial cell migration by CHM-1 was
observed with lower concentration (0.1–1 M). We also found
that the microtubule polymerization of HUVEC was disrupted
by CHM-1 (supplemental Fig. S1). Based on these results, we
conclude that CHM-1 may be a novel vascular targeting agent
for cancer treatment.
The mechanisms of vascular target therapies include pre-
venting the formation of new blood vessels or revascularization
and/or disrupting the existing vasculature of a tumor. Endothe-
lial cell apoptosis plays a pivotal role in the sculpting of blood
vessels (31). It has been reported that the induction of endothe-
lial cell apoptosis may represent a
common feature among antiangio-
genic molecules (6, 32). Accumulat-
ing evidence suggests that many
cytotoxic agents and antiangiogenic
inhibitors act via the induction of
endothelial cell apoptosis to sup-
press endothelial cell proliferation
or migration and then to restrict
tumor progression (33, 34). In this
study, we found accumulation of
cells at the G2/M phase in CHM-1-
treated cells. We also measured the
effect of CHM-1 on the cell cycle
regulatory proteins. The results of
this study show that CHM-1 did not
alter the level of Cdc2 expression,
but it did cause a dramatic increase
of MPM2, cyclin B1 protein expres-
sion, and Cdc25C phosphorylation.
Moreover, Tyr-15-phosphorylated
Cdc2 expression was decreased
and Thr-161-phosphorylated Cdc2
expression was increased after
CHM-1 treatment at the indicated
times (supplemental Fig. S2). These
results are similar with those
reported by Wang et al. (24). The
results of flow cytometric analysis
were also shown at an elevated
sub-G1 peak in CHM-1-treated
cells, reflecting the effect of apopto-
sis. We confirmed this by detecting
apoptotic morphological and bio-
chemical features of the cells. These
data suggest that CHM-1 might
induce apoptosis in proliferating
endothelial cells.
Caspases play a critical role in apoptosis and in development.
Recent evidence indicates two major types of signaling path-
ways in activated caspase-8 amplify apoptotic signals as follows:
one directly cleaves and activates downstream effector caspases
such as caspase-3/7, and the second activates the intrinsic apo-
ptotic pathway by processing Bid, which is an intracellularmol-
ecule that bridges the apoptotic interaction between the mem-
brane DRs and the mitochondria. The cleaved Bid is then
translocated into the mitochondria, and through subsequent
interaction with pro-apoptotic Bax, the mitochondria-depen-
dent apoptotic pathway is stimulated, thereby activating
caspase-3/7 (35, 36). However, our previous study demon-
strates that neither initiator nor effector caspases participate in
CHM-1-mediated apoptosis in human hepatocellular carci-
noma cells. CHM-1 appears to induce apoptotic cell death via
the caspase-independent pathway (24). The results of this study
show that proteolytic procaspase-8, -3, and -7 are cleaved but
procaspase-9 is not. Caspase-3 processing and subsequent
PARP cleavage can be prevented by addition of the caspase
inhibitor Z-VAD-fmk (Fig. 4). Furthermore, treatment with
FIGURE 6. Contribution of p53 to CHM-1-induced apoptosis in HUVEC. A, CHM-1-induced p53 expression in
HUVEC. Treatment with CHM-1 (3 M) for the indicated times, either total cellular (upper panel) or nuclear
lysates (lower panel), was subjected to Western blot analysis using antibody specific for p53. B, inhibition of p53
activation contributed to the down-regulation of DR5 in CHM-1-treated cells. HUVEC were pretreated with or
without p53 siRNA for 48 h and then incubated with or without CHM-1 (3 M) for 24 h. Upper panel, total cellular
lysates were subjected to Western blot analysis of DR5, PARP, and caspase-3. Lower panel, expression of DR5
mRNA was demonstrated by RT-PCR. C, control or DR5 siRNA-transfected HUVEC were treated with CHM-1 (3
M) for 24 h. Left panel, cell viability was measured by crystal violet assay and expressed as a percentage of the
untreated control. Right panel, cells stained with propidium iodide and the percentage of cells in the sub-G1
phase (reminiscent of apoptotic cells) were estimated by FACScan flow cytometric analysis. GAPDH, glyceral-
dehyde-3-phosphate dehydrogenase.
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CHM-1 in HUVEC does not induce the cleavage of protein Bid
(supplemental Fig. S3). These results indicate that CHM-1 trig-
gers apoptosis in HUVEC by the extrinsic caspase-dependent
pathway.
Within the extrinsic apoptotic pathway, caspase-8 is the
most proximal caspase that transmits apoptotic signals origi-
nating at the membrane DRs (36). We reasoned that if CHM-1
results in activation of caspase-8, it should be through the up-
regulation of DRs in HUVEC. The data indicate that CHM-1
increased the expression of DR5, but not DR4 and Fas, and that
the effects weremanifested not only in protein levels but also in
the cell surface fraction in HUVEC. On the other hand, TRAIL
induces apoptosis by activating caspase-8 via its receptors DR4
and/or DR5 (16). HUVEC express both DR4 andDR5, and apo-
ptosis is induced following treatment with TRAIL (37). Recent
studies, however, indicate that DR levels can be enhanced by
endogenous induction or exogenous overexpression. Several
genotoxic and nongenotoxic agents can induce apoptosis by
increasing endogenous DR5 (38). On the other hand, exog-
enously overexpressed DR5, without concomitant up-regula-
tion in its ligand levels, has been shown to be associated with
induction of apoptosis (39). In this study, our results demon-
strated that CHM-1-induced apoptosis is coupled with DR5
induction without changes in the expression of its ligand,
TRAIL. It is therefore possible that CHM-1 activated DR5 to
induce cell death in a ligand-independent manner. The up-reg-
ulation of DR5mRNAwas also seen as early as 1 h after CHM-1
treatment and was coupled with similar changes at the protein
level. Moreover, we found that DR5 siRNA efficiently pre-
vented the expression of cleaved forms of caspase-3 and PARP
and growth inhibition after CHM-1 treatment.
p53 is amajor tumor suppressor protein that exerts its effects
on multiple aspects of tumor formation. As a sensor of cellular
stress, the p53 tumor suppressor protein is a well established
critical apoptosis initiator that contributes to the cellular emer-
gency-response mechanism (12). Previous evidence has dem-
onstrated that p53 is involved in the paclitaxel (taxol)-induced
growth arrest or apoptosis in HUVEC (40), adenovirus-medi-
ated p53 transfer (41), pigment epithelial-derived factor (42),
and 15-deoxy	12,14-prostaglandin J2 (43). These findings
prompted us to investigate the involvement of p53 in CHM-1-
induced HUVEC apoptosis. As shown in Fig. 6A, we found that
treatment with CHM-1 induced the expression of p53 and its
accumulation in the nucleus. Moreover, the concentration of
CHM-1 required to increase p53 protein expression was the
same as that needed to induce apoptosis. Thus, we suggest that
p53may be involved inCHM-1-triggered apoptosis inHUVEC.
In response to various stress-associated signals, p53 stimulates
a wide network of signals that act through two major apoptotic
pathways, the extrinsic DR pathway or intrinsic mitochondrial
pathway, and consequently triggers the activation of a caspase
cascade. Furthermore, p53 exerts its apoptotic functions by
transcriptionally activating an ever-increasing number of target
genes that in turn lead directly or indirectly to cell death (12).
Evidence indicates that p53 can activate the extrinsic DR path-
way through the induction of genes encoding transmembrane
proteins such as DR5 (39).We therefore examined whether the
induction of DR5 expression by CHM-1 in HUVEC correlated
with p53 status. The representative result shown in Fig. 6B indi-
cates that knockdown of p53 by p53 siRNA can inhibit both
protein andmRNA expression levels of DR5. These results sug-
gest that CHM-1 induced the up-regulation of DR5 mediated
by p53 induction. This study showed that p53 activation was
critical for CHM-1-induced apoptosis, because knockdown of
p53 blocked/inhibited CHM-1-mediated apoptosis. On the
other hand, transfected p53 siRNA into HUVEC clearly sup-
pressed CHM-1-induced cleavage of caspase-3 and PARP and
dramatically reversed CHM-1-induced cell growth inhibition
(Fig. 6, B and C). Overall, these results identify p53 as a crucial
proapoptotic protein in apoptosis induced by CHM-1 in
HUVEC.
In conclusion, our study demonstrates that CHM-1 exhibits
a potent antineovascularization effect in vitro and in vivo, inter-
fering with several pivotal steps in the neovascularization proc-
ess, including endothelial cells growth, migration, and differen-
tiation (capillary tube formation). Our results also show that
CHM-1 induces HUVEC apoptosis through up-regulation of
p53 and subsequent induction of DR5-mediated extrinsic apo-
ptotic signaling pathways. The ability to induce HUVEC apo-
ptosis in vivo suggests that CHM-1 can prevent the formation
of new blood vessels and can also eliminate existing vessels
within tumors. These observations provide the pharmacologi-
cal basis for developing CHM-1 for therapeutic application in
pathological angiogenesis-related diseases such as cancer.
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